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Abstract
Background:  To compare the dosimetric advantage of three different intensity-modulated
radiation therapy (IMRT) plans to a three dimensional (3D) conventional radiation treatment for
anal cancer with regards to organs-at-risk (OAR) avoidance, including iliac bone marrow.
Methods: Five patients with T1-3 N0-1 anal cancer and five with T4 and/or N2-3 tumors were
selected. Clinical tumor volume (CTV) included tumor, anal canal and inguinal, peri-rectal, and
internal/external iliac nodes (plus pre-sacral nodes for T4/N2-3 tumors). Four plans were
generated: (A) AP/PA with 3D conformal boost, (B) pelvic IMRT with conformal boost (C) pelvic
IMRT with IMRT boost and (D) IMRT with simultaneous integrated boost (SIB). The dose for plans
(A) to (C) was 45 Gy/25 followed by a 14.4 Gy/8 boost, and the total dose for plan (D) (SIB) was
59.4 Gy/33. Coverage of both PTV and the volume of OAR (small bowel, genitalia, iliac crest and
femoral heads) receiving more than 10, 20, 30, and 40 Gy (V10, V20, V30, V40) were compared
using non parametric statistics.
Results: Compared to plan (A), IMRT plans (B) to (D) significantly reduced the V30 and V40 of
small bowel, bladder and genitalia for all patients. The V10 and V20 of iliac crests were similar for
the N0-1 group but were significantly reduced with IMRT for the N2-3/T4 group (V20 for A =
50.2% compared to B = 33%, C = 32.8%, D = 34.3%). There was no statistical difference between
2-phase (arm C) and single-phase (SIB, arm D) IMRT plans.
Conclusion: IMRT is superior to 3D conformal radiation treatment for anal carcinoma with
respect to OAR sparing, including bone marrow sparing.
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Background
The standard of care for the curative treatment of anal
canal carcinoma has evolved over the past three decades,
from abdomino-perineal resection and life-long colos-
tomy to organ preservation therapy using combined radi-
ation and chemotherapy. Organ preservation is now
achieved in more than 70% of cases [1-7]. The downfall of
this approach is significant acute toxicity in the form of
moist desquamation, genitourinary and gastrointestinal
effects, and hematologic compromise. In turn, this can
lead to undue treatment breaks and long overall treatment
times that may negatively influence outcome [8,9]. To
compound the difficulty of decreasing side-effects, retro-
spective data also seems to indicate a positive impact on
local control of dose escalation to or above 54 Gy [10-12].
While the high acute toxicity associated with this treat-
ment might be reduced by an alternate chemotherapy reg-
imen, this approach remains investigational.
In other cancers faced with similar difficulty, it has been
shown that side effects may be reduced by using more
conformal therapy in the form of intensity-modulated
radiation therapy (IMRT) [13-20]. IMRT is well suited for
anal cancer because of the many critical structures adja-
cent to the target volume, which receive significant doses
with conventional (AP-PA) field arrangements or 3D con-
formal treatment. This approach has already been investi-
gated at the University of Chicago [21] where 17 patients
were treated with IMRT, thereby reducing the mean and
threshold doses to the small bowel, bladder, and genita-
lia/perineum compared to conventional treatment. There
were no delays attributable to gastrointestinal or skin tox-
icity. However, slightly worse hematologic toxicity (53%
grade 3–4 acute blood/bone marrow toxicity) were
reported compared to other studies. It was hypothesized
that this was the result of higher radiation threshold doses
to iliac bone where most of the adult bone marrow reserve
lies. The IMRT optimization had taken into account the
iliac bone as a posterior "blocking" structure but without
specific dose constraints.
Considering these results, our goal was to find an optimal
radiation protocol which can treat anal cancer at high
doses while providing not only gastrointestinal and der-
matologic but also adequate iliac bone marrow sparing.
We designed a study that compares three different IMRT
plans delivering 59.4 Gy in 33 fractions for each of 10
patients to a conventional three-dimensional AP-PA plan
followed by a 3-dimensional conformal radiotherapy (3D
CRT) boost (plan A). The three IMRT plans were: a pelvic
IMRT plan followed by a 3D CRT boost (plan B), a pelvic
IMRT plan followed by a sequential IMRT boost (plan C)
and finally, an IMRT plan with simultaneous integrated
boost (SIB, plan D). Our findings are presented here along
with a review of pertinent IMRT planning studies of anal
cancer.
Methods
Simulation, target contouring and fractionation
Ten patients previously treated with curative intent chem-
oradiation at the Val d'Aurelle-Paul Lamarque Cancer
Institute (Montpellier, France) during the last 2 years were
selected. Criteria for inclusion were that patients must
have had complete imaging of iliac crests on the planning
simulation scan to permit dose-volume histogram (DVH)
comparisons of iliac bone marrow. Five patients were
staged T1-3 N0-1 and the remaining five were T4 and/or
N2-3 tumors according to the 6th edition of the American
Joint Committee on Cancer staging manual. Details of
staging are shown in Table 1.
Patients were simulated in the supine position without a
custom immobilization device using a planning CT scan
(PQ 2000 CT Simulator, Marconi Medical Systems, Cleve-
land, OH) with 4 mm thick slices. Intravenous contrast
and an anal marker were recommended but were not
compulsory.
Relevant structures were manually contoured on each
axial CT scan slice by a single radiation oncologist. The
gross tumor volume (GTV) was contoured based on find-
ings from physical examination, diagnostic CT scan, MRI
and endoscopic ultrasound in all patients. The clinical tar-
get volume 1 (CTV1) consisted of the GTV expanded by a
three-dimensional 1 cm margin, the anal canal, and the
draining lymphatic regions, including the perirectal, inter-
nal iliac, external iliac, obturator and inguinal lymphatics
in all cases. For the five patients with N2–3 and/or T4
tumors, the pre-sacral nodes were also included. These
nodal regions were defined by encompassing the contrast
enhanced vessels with a 1 cm margin. The perirectal
region was defined as the rectal wall and the fat contain-
ing mesorectum. Finally, the CTV1 was uniformly
expanded by 1 cm to produce the planning target volume
Table 1: Patient tumor staging
N0–N1 group N2–N3/T4 group
No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 No. 7 No. 8 No. 9 No. 10
T2 N0 T3 N0 T3 N0 T2 N1 T3 N1 T4 N2 T1 N2 T4 N1 T3 N2 T4 N2Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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1 (PTV1). The boost volume (PTV2) consisted of the pre-
treatment GTV expanded radially by 1.5 cm. OAR
included the small bowel, bladder, perineum and external
genitalia (penis and scrotum in men and vulva in
women), iliac crests (from bony top to the superior part of
acetabulum inferiorly) and femoral heads. No additional
margin around OAR was used to account for possible inter
or intra fraction motion. Depending on patient anatomy,
anterior and/or posterior blocking structures could be
used in the IMRT planning process. Dose distributions did
not take into account corrections for tissue heterogenei-
ties.
Conventional three-dimensional planning
Arm A consisted of conventional three-dimensional AP/
PA fields plans to 45 Gy in 25 fractions in phase 1 fol-
lowed by a 3D conformal 3-field boost to 59.4 Gy. Using
the PTV described above and taking into account the
beam penumbra, the resulting field borders for the AP and
PA fields were: upper limit at the level of S2–S3 for N0-1
tumors and at the level of L5-S1 for N2-3 and T4 tumors,
lower border at 2.8–3 cm below the tumor. The lateral
limits where set at the antero-superior iliac spine. Multi-
leaf collimators were used to adjust dose conformation
around the PTV. Six and 18 MV photons were used for the
AP and PA fields, respectively. The radiation dose was pre-
scribed to the PTV, such that 100% of the PTV received >
95% of the prescribed dose and that no region in the field
received greater than 107% of the prescribed dose. Varia-
ble weighting of the fields and wedges were used to opti-
mize the plan and improve dose homogeneity. Direct
electron beams could be used to supplement the dose to
the inguinal regions as needed.
IMRT planning
Arms B, C and D used IMRT plans generated by a commer-
cial inverse planning software (Eclipse, Helios, version
7.2.34, Varian, Palo Alto, CA) and sliding window tech-
nique. Beam geometry consisted of seven non-coplanar
fields for the whole pelvis (phase 1) with the following
gantry angles: 0°, 45°, 110°, 165°, 195°, 250° and 325°.
A 5-field technique was used for the IMRT boost of arm C
(45°, 110°, 180°, 250° and 315°). Patients were treated
with an 18 MV linear accelerator with dynamic multileaf
collimator (21 EX, Varian, Palo Alto, CA). This energy was
chosen for IMRT because the resulting plans have less
complex fluence maps and require fewer monitor units as
compared to those generated with 6 MV photons.
Arm B consisted of pelvic IMRT delivering 45 Gy in 25
fractions to PTV1 in phase 1 followed by a conformal 5-
field radiotherapy boost to PTV2 for a total dose of 59.4
Gy in 33 fractions. Arm C consisted of the same pelvic
IMRT phase 1 of 45 Gy as in Arm B but the subsequent
boost to PTV2 was delivered with IMRT, for a total dose of
59.4 Gy in 33 fractions. Finally, arm D consisted of pelvic
IMRT with a SIB delivering 49.5 Gy in 33 fractions (bio-
logical equivalent dose of 45 Gy in 25 fractions for early
response tissues) to PTV1 and 59.4 Gy in 33 fractions to
PTV2.
The PTV and OAR optimization constraints were itera-
tively adjusted in Helios until a clinically acceptable treat-
ment plan was obtained. Typical optimization parameters
of OAR for IMRT planning are shown in Table 2.
Dose-volume histograms (DVH) were generated for all of
these structures. Treatment plans were evaluated using vis-
Table 2: Typical OAR optimization parameters for IMRT
Organ Threshold dose (Gy) Volume above limit (%)
Bladder 30 80
40 40
05 0
Small Bowel 30 40
40 30
05 0
Genitalia/perineum 30 35–45
40 5–10
04 8
Iliac crests 10 35–45
20 25–30
05 0
Femoral heads 45 5
05 5Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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ual inspection and evaluation of dose distributions on the
CT-slices as well as DVH analysis. For a plan to be consid-
ered clinically acceptable, 95% of the PTV must have
received ≥ 95% of the prescribed dose, no region could
receive more than 65 Gy (109% of the prescribed dose)
and doses to OAR were minimized.
Statistical Analysis
The mean percentage volume of bladder, genitalia/peri-
neum, and small bowel receiving more than 30 and 40 Gy
(V30 and V40) were calculated from the plans, as well as
the mean percentage volume of iliac crests receiving more
than 10 and 20 Gy (V10 and V20). A two sample Wil-
coxon rank-sum (Mann-Whitney) test was used for all
comparisons between treatment techniques. The three
planning techniques incorporating IMRT (arms B, C, and
D) were each compared with the conventional 3D plan
(arm A), and then arm C was compared to arm D. A p
value less than 0.05 was used to indicate statistical signif-
icance.
Results
Comparison of target volume coverage between IMRT and 
conventional 3D plans
All treatment plans showed adequate coverage of the tar-
get volume, with more than 95% of volume of PTV1 and
PTV2 receiving greater than 95% of the prescribed dose.
Also, 98% of the target volume received more than 90%
of the prescribed dose in all cases. Evaluation of homoge-
neity using maximum dose to PTV 1 and PTV 2 was lower
with the IMRT plans (Arms B to D) than with the conven-
tional 3D plans (Arm A). For arms B to D, the mean vol-
ume of PTV receiving more than 107% of the prescribed
dose was 0.003% for PTV 1 and 0.016% for PTV 2. Fur-
thermore, no volume received more than 110% for any
plan.
Dose distributions by treatment arm on the same axial CT slice through both target volumes (PTV1 and PTV2) and the exter- nal genitalia in a female patient Figure 1
Dose distributions by treatment arm on the same axial CT slice through both target volumes (PTV1 and PTV2) and the exter-
nal genitalia in a female patient. This CT slice shows the sparing of the genitalia by the 45 Gy isodose curve in arms B, C, and D 
as compared with arm A.Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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Figure 1 shows typical sparing of the genitalia from the
total dose prescribed to PTV1 in the IMRT arms as com-
pared to conventional 3D plans. This is also shown in Fig-
ure 2, where sparing of the small bowel can equally be
noted.
Comparison of OAR sparing between IMRT and 
conventional 3D plans
Incorporation of IMRT in phase 1 or in phase 1 and 2 sig-
nificantly reduced the volume of bladder and genitalia/
perineum receiving ≥ 30 Gy and ≥ 40 Gy for N0-1 and N2-
3/T4 patients as compared to conventional 3D plans
(Tables 3 and 4). For example, the mean volume of geni-
talia/perineum receiving ≥ 40 Gy is 7% and 3% for arms
C and D compared to 80% with the conventional 3D plan
for N0-1 patients (p  < 0.05). Similarly, for N2-3/T4
patients, 9% and 7% of the genitalia received ≥ 40 Gy for
arms C and D compared to 85% with the conventional 3D
plan (p < 0.05). There is also significantly less small bowel
receiving ≥ 30 Gy and ≥ 40 Gy for both patient groups
using IMRT, although this did not reach statistical signifi-
cance for the V30 for the IMRT with SIB (arm D) com-
pared to the conventional 3D treatment (p = 0.07 for both
patient groups).
The results are shown separately in Table 3 for the N0-1
patients and Table 4 for N2-3/T4 patients since the upper
field limit was different for the two groups which influ-
ences the dose to OAR, particularly to the iliac crests and
small bowel.
Dose distributions by treatment arm on the same coronal CT slice through both target volumes and avoidance structures Figure 2
Dose distributions by treatment arm on the same coronal CT slice through both target volumes and avoidance structures. This 
CT slice also shows the sparing of the external genitalia, small bowel and iliac crests in arms B, C, and D as compared with arm 
A.Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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Also, since high doses to even a small volume of small
bowel may be thought to be deleterious, we computed the
maximum dose to 1% (D1) of the small bowel (Table 5).
Interestingly, patient n°8 would have received close to the
prescribed dose if treated with arm A. He presented a large
primary tumor which extended superiorly into the rec-
tum, invaded the prostate and lead to a recto-vesical fis-
tula. For this patient, the D1 for arms C and D were 52 and
49.5 Gy, respectively, which compare favorably to the
58.5 Gy of the conventional 3D plan (arm A).
The mean volume of iliac crests receiving ≥ 10 Gy and ≥
20 Gy was similar between the four treatment arms for
N0-1 patients, ranging from 37 to 40% for the V10 and 28
to 34% for the V20. However, for N2-3 and/or T4 patients
with an upper field limit at L5-S1, significant iliac bone
marrow sparing was found with all but one (V10 with arm
D) treatment arms utilizing IMRT compared to the con-
ventional 3D treatment. The absolute BMS gain for the
V20 is between 15 and 17%, with a V20 of 50.2% for arm
A compared to 33, 32.8, and 34.3% for arms B, C, and D,
respectively (all p < 0.05).
The volume of femoral heads receiving ≥ 4 5  G y  w a s
reduced with all plans incorporating IMRT compared to
the conventional 3D plan for both patient groups and the
mean dose to the femoral heads was similar in all treat-
ment plans.
Figures 3 and 4 depict mean DVHs by treatment arm for
OAR according to treatment groups.
Additional comparison between IMRT plans
We carried out comparisons of all evaluated endpoints
between the two treatments arms consisting solely of
IMRT (arms C and D). We failed to find any significant
statistical differences between these two treatment plans
with respect to target volume coverage and critical organ
sparing.
Table 3: Mean percent volume of OAR receiving various dose levels for N0–N1 patients (upper limit of fields at S2–S3) for a 59.4 Gy 
treatment
Mean volume receiving above threshold dose (%) †
Organ Threshold dose (Gy) A B C D
Bladder 30 100 87.8* (80–95) 86.7* (78–92) 80.8* (74–83)
40 100 65.2* (55–76) 57.4* (43–69) 46.2* (35–55)
Genitalia/perineum 30 85.8 (72–99) 47.6* (23–88) 36.4* (23–52) 26.6* (13–44)
40 80.4 (65–98) 20.2* (0–54) 7.2* (0.2–18) 2.7* (0–7)
Small bowel 30 59.3 (37–72) 40.1* (28–49) 39.6* (28–48) 39.7 (29–45)
40 56.1 (35–68) 25.0* (17–31) 24.5* (16–30) 26.7* (19–30)
Iliac crests 10 39.8 (33–52) 37.4 (33–44) 37.1 (33–44) 39.6 (35–47)
20 33.7 (28–47) 28.4 (26–30) 28.2 (26–30) 28.3 (27–30)
Femoral heads 45 33.8 (25–51) 23.3 (8–45) 14.6* (2–30) 20.9* (12–30)
†Mean in % (range).
* denotes statistically significant p values (p < 0.05) as compared with arm A.
Table 4: Mean percent volume of OAR receiving various dose levels for N2-3 and/or T4 patients (upper limit of fields at L5-S1) for a 
59.4 Gy treatment
Mean volume receiving above threshold dose (%)†
Organ Threshold dose (Gy) A B C D
Bladder 30 100 88.6* (76–100) 84.9* (71–99) 77.0* (68–84)
40 100 60.2* (43–74) 52.5* (39–70) 39.0* (30–54)
Genitalia/perineum 30 87.0 (60–100) 64.4 (26–93) 46.2* (26–68) 32.8* (20–53)
40 85.1 (56–99) 25.9* (2–43) 9.8* (1–26) 7.4* (0–26)
Small bowel 30 64.4 (48–89) 43.6* (38–52) 43.0* (37–50) 45.8 (39–55)
40 62.1 (45–87) 26.5* (21–30) 25.8* (19–30) 28.3* (20–35)
Iliac crests 10 59.9 (57–63) 52.2* (45–57) 51.4* (45–56) 56.0 (47–60)
20 50.2 (47–54) 33.0* (30–37) 32.8* (30–37) 34.3* (30–38)
Femoral heads 45 29.9 (21–39) 15.7* (8–21) 8.8* (6–14) 14.6* (11–17)
†Mean in % (range).
* denotes statistically significant p values (p < 0.05) as compared with arm A.Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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Table 5: Dose received (Gy) by 1% of the small bowel (D1)
volume (cc) A B C D
No. 1(T2 N0) 599 51.5 46 46 47.5
No. 2 (T3 N0) 631 47 45.5 45 50
No. 3 (T3 N0) 670 51.5 48 47 49
No. 4 (T3 N1) 1434 48 47.5 47 49
No. 5 (T3 N1) 759 54.5 53.5 51.5 49.5
No. 6 (T4 N2) 1080 54 52.5 52 49.5
No. 7 (T1 N2) 2046 51.5 45.5 44.5 48.5
No. 8 (T4 N1) 859 58.5 56.5 52 49.5
No. 9 (T3 N2) 938 48 48 47.5 49
No. 10 (T4 N2) 1252 49 47.5 47.5 50
(3A), Mean Dose-Volume Histograms (DVH) for iliac crests of N0-1 group Figure 3
(3A), Mean Dose-Volume Histograms (DVH) for iliac crests of N0-1 group. Arm A, blue; arm B, brown; arm C, yellow; arm D, 
green; (3B), Mean Dose-Volume Histograms (DVH) for genitalia/perineum of N0-1 group. Arm A, blue; arm B, brown; arm C, 
yellow; arm D, green; (3C), Mean Dose-Volume Histograms (DVH) for small bowel of N0-1 group. Arm A, blue; arm B, brown; 
arm C, yellow; arm D, green.Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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Discussion
Concurrent chemoradiation is the established standard of
care for locally advanced carcinoma of the anal canal.
Attempts to decrease the important side-effects of this
treatment by modifying the chemotherapy regimen with
the suppression of Mitomycin-C (MMC) have resulted in
increased loco-regional recurrence and higher colostomy
rates [5,7]. Furthermore, a recent Intergroup trial led by
the RTOG to evaluate the possible replacement of MMC
by induction and concomitant cisplatin (CDDP) has
shown disappointing preliminary results, with a non-sta-
tistically significant higher colostomy rate in the CDDP
arm, which was however better tolerated in terms of
hematologic toxicity [22]. While longer follow-up is
needed, at present MMC still plays a major role in the
management of carcinoma of the anal canal.
As well, decreasing the radiation dose or using split-course
techniques is no longer recommended. Instead, several
groups have focused their attention on modifying the
radiation delivery technique using a 3D-CRT "diamond
technique" [23,24] or through IMRT [21,25,26]. While
IMRT has successfully reduced small bowel, perineal and
genitalia doses, hematologic toxicity remains a clinical
concern. This is in part because a large proportion of the
body bone marrow reserve is located within the lumbar
spine and pelvic bones [27]. Moreover, apart form the
ovaries, the bone marrow is the most radiosensitive pelvic
tissue [28], and concurrent chemotherapy likely lowers
this threshold dose and is in itself myelotoxic.
The issue of chemotherapy-induced bone marrow sup-
pression worsened by pelvic irradiation has been studied
(4A), Mean Dose-Volume Histograms (DVH) for iliac crests of N2-3/T4 group Figure 4
(4A), Mean Dose-Volume Histograms (DVH) for iliac crests of N2-3/T4 group. Arm A, blue; arm B, brown; arm C, yellow; arm 
D, green; (4B), Mean Dose-Volume Histograms (DVH) for genitalia/perineum of N2-3/T4 group. Arm A, blue; arm B, brown; 
arm C, yellow; arm D, green; (4C), Mean Dose-Volume Histograms (DVH) for small bowel of N2-3/T4 group. Arm A, blue; 
arm B, brown; arm C, yellow; arm D, green.Radiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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in patients with gynecologic malignancies. Brixey et al.
[20] showed that intensity-modulated whole pelvic radio-
therapy (IM-WPRT) decreased the number of women
experiencing Grade 2 or greater white blood cell count
(WBC) toxicity as compared with conventional WPRT in
36 patients receiving chemotherapy. This resulted in
chemotherapy being held back less often for hematologic
toxicity. Of note, these benefits in hematologic toxicity
were initially seen without explicitly using a bone marrow
sparing (BMS) radiation technique. Subsequently, the
same group used BMS IM-WPRT and significantly reduced
the volume of bone marrow receiving > 18 Gy compared
with both IM-WPRT and 4 field box techniques [29].
In the current trial, we compared four radiation delivery
techniques with the intent of determining the optimal reg-
imen that achieves maximal target volume coverage and
provides adequate gastrointestinal and dermatologic spar-
ing without compromising the bone marrow. We have
shown that using BMS IM-WPRT throughout the entire
treatment (arms C and D) is feasible and reduces thresh-
old radiation doses to the small bowel, bladder, genitalia
and femoral heads as compared to conventional AP/PA
plans with 3D conformal boost. The mean values that we
obtained for these critical structures with a prescription
dose of a 59.4-Gy treatment are comparable to those
obtained by Milano et al. [21] in their IMRT treatment arm
with a dose of 45 Gy. This was achieved in our study with
both N0–N1 tumors with an upper field border at the
level of S2–S3 and in N2–N3/T4 tumors with an upper
field border at the level of L5-S1 that allowed proper cov-
erage of the mesorectal and presacral nodes.
Furthermore, BMS WP-IMRT provided comparable mean
and threshold doses to the iliac crests in N0–N1 tumors,
but statistically reduced mean and threshold doses to this
structure in N2-3 and/or T4 tumors. The mean V10 and
V20 for our N2-3/T4 tumor patient subgroup were 53 and
33%, respectively, compared to the 73% and 59%
obtained by Milano et al. [21]. Whether these lower doses
to iliac bone marrow will result in less acute hematologic
toxicity remains to be seen in further clinical studies.
The dose given to femoral heads in our trial deserves more
discussion. Although the volume of femoral heads receiv-
ing  ≥ 45 Gy was reduced with all plans incorporating
IMRT compared to the conventional 3D plan, it was
higher than expected. In comparison, Hsu et al. [26]
treated five patients with T2 N0-1 tumors with definitive
chemo-radiation using IMRT plans. For each patient, AP/
PA plans with supplemental inguinal electrons boosts, 4-
field box, 7-field IMRT, and 7-field IMRT integrated boost
plans were generated. The volume of bowel and bladder
receiving threshold doses were similar to ours, but the V45
of the femoral heads is 0% in both of their IMRT arms,
which is much less than what we obtained. This may be
explained by several factors including different definitions
of target volumes, more stringent dose constraints used in
their study (i.e. femoral head V45 < 1%) and the smaller
tumor sizes of their patients which were all staged T2 N0-
1. Furthermore, the mean V20 for the iliac crests was 77%
for both their IMRT arms as compared with 28% and 33%
in our N0-1 and N2-3/T4 groups, respectively. Interest-
ingly, Milano et al. [21] noted higher than expected hema-
tologic toxicity with an iliac crest V20 of 59% and V10 of
73%. It is possible that sparing of the femoral heads and/
or other organs comes at the cost of increasing dose to the
iliac crests. The results of our study reinforce the idea that
specific dose constraints for all OAR must be considered
during the IMRT optimization process in anal cancer,
namely with regards to the iliac crests.
Another study which focused on femoral head dose was
published by Chen et al. [25]. They compared 7 coplanar
fields IMRT with conventional plans for the coverage of
pelvic and inguinal/femoral nodes in two patients with
anal cancer. The whole pelvic dose was 36 Gy in 20 frac-
tions. The mean dose to the femoral head was 58.3% and
59.5% of the prescription dose for their 2 patients using
conformal avoidance IMRT. Similarly, the mean dose to
the femoral head with the IMRT plans in our study ranged
from 52.2% to 56.5% of the prescribed dose. This con-
firms that the whole pelvis may be treated to 45 Gy with
an additional 14.4 Gy boost to the tumor while keeping
the mean dose to the femoral heads at a relatively con-
stant percentage of the prescription dose.
A third IMRT study using a single-phase dose painting
technique has been described by the Boston Medical
Center and Massachusetts General Hospital. Six patients
were treated (in text, RTOG 0529 protocol draft, p.11)
and dose-painting IMRT provided better normal tissue
sparing than 3D CT-based conformal therapy plans. No
patient required a treatment break of more than one week
and all patients completed therapy as initially planned.
Comparisons with our dosimetric study are limited since
they did not use the same threshold OAR doses. However,
the mean V30 and V40 values for the bladder were similar
to ours, whereas our mean V30 values for the genitalia
were similar or lower than the mean V35 that they
obtained. However, they achieved lower V30 and V40 val-
ues for the small bowel and much lower V45 for the fem-
oral heads. Differences may be due to the lower total dose,
which ranged from 42 to 45 Gy to elective nodes and from
50.4 to 54 Gy to gross tumor. The RTOG is currently accru-
ing patients for a phase II trial of dose-painted IMRT.
There was no significant difference between the 2-phase
(arm C) and single-phase IMRT plans (arm D). Both of
these arms seem superior, at least for genitalia sparing, toRadiation Oncology 2007, 2:41 http://www.ro-journal.com/content/2/1/41
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arm B although there was no statistical analysis compar-
ing these treatment arms. As for the greater volume of iliac
crest receiving doses above 45 Gy observed in the DVH of
arm D (Fig. 3), this difference is not clinically significant
since it is probable that theses segments of marrow are not
functional after having received 45 Gy. Also, the doses
shown in the DVH are physical doses. If we consider the
radiobiological equivalent dose calculated in daily 1.8 Gy
fractions for the SIB arm (arm D), the DVH will be shifted
to the left and 49.5 Gy in 1.5 Gy fractions would be
approximately equivalent to 45 Gy in 1.8 Gy fractions.
Conclusion
BMS-IMRT in the treatment of anal canal cancer reduces
dose to surrounding normal structures compared with
conventional 3D AP/PA planning followed by a confor-
mal boost. Other single institution studies have shown
that this treatment is well tolerated and decreases acute
toxicity and treatment breaks. Longer follow-up is needed
to determine if late toxicity will be reduced and if loco-
regional control and survival will be equivalent. In our
center, we have determined that a single-phase IMRT
treatment with simultaneous integrated boost is dosimet-
rically equivalent and more convenient than two-phase
treatment techniques since there is only one optimization
and quality assurance session by the physicist. This
approach is currently being evaluated in phase II proto-
cols by our institution and by the RTOG. A more stand-
ardized approach to target volume definition and dose
prescription for IMRT of the anal canal is warranted.
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